NEXGEL (NXGL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Jun, 2026Executive summary
The annual meeting will address seven proposals, including director elections, approval of significant share issuances, reincorporation to Nevada, increases in authorized shares, a reverse stock split, executive compensation, and auditor ratification.
The Board recommends voting in favor of all proposals, emphasizing the importance of shareholder participation.
The meeting is scheduled for July 10, 2026, with proxy materials available online and by mail.
Voting matters and shareholder proposals
Seven proposals include: election of seven directors, approval of share issuance exceeding 19.99% for private placements, reincorporation to Nevada, increase in authorized shares, discretionary reverse stock split, advisory vote on executive compensation, and auditor ratification.
Proposals 4 and 5 serve as Delaware-law fallbacks if reincorporation (Proposal 3) is not approved.
Approval thresholds vary: most require a majority of outstanding shares, while director elections require a plurality.
Shareholders may vote by internet, phone, or mail, and can revoke proxies before the meeting.
Board of directors and corporate governance
Seven directors are nominated, with detailed biographies provided for each.
Five directors are independent per Nasdaq standards; the CEO and one director are not independent due to related party transactions.
The Board has Audit, Compensation, and Nominating & Corporate Governance Committees, all with independent members.
The Board held seven meetings in 2025, with all directors attending at least 75% of meetings.
The company has a Code of Business Conduct and Ethics, insider trading and hedging policies, and a compensation recovery policy.
Latest events from NEXGEL
- Expanded regenerative medicine portfolio and direct sales force set stage for rapid growth.NXGL
Planet MicroCap Las Vegas 202617 Jun 2026 - Annual meeting seeks approval for director elections, stock issuance, reincorporation, and capital changes.NXGL
Proxy filing29 May 2026 - Major acquisition expected to triple annual revenue and improve profitability.NXGL
Q1 202615 May 2026 - Revenue up 31.5% to $11.4M, but net loss of $3.0M and going concern risks persist.NXGL
Q4 202523 Apr 2026 - Acquisition and partnership triple revenue, drive profitability, and expand into regenerative medicine.NXGL
M&A announcement21 Apr 2026 - Hydrogel innovation and strategic partnerships fuel rapid growth and expanding product lines.NXGL
Planet MicroCap Showcase: VEGAS 20253 Feb 2026 - Record Q2 revenue and strong outlook driven by branded products and Silly George growth.NXGL
Q2 20242 Feb 2026 - Q3 revenue up 141% to $2.94M, gross margin 43.6%, but losses and risks persist.NXGL
Q3 202414 Jan 2026 - Strong growth from product innovation, acquisitions, and major partnerships, with profitability in focus.NXGL
IAccess Alpha–Buyside Best Ideas Winter Virtual Conference 202411 Jan 2026